An Act Concerning Pharmacy Benefits Manager Reform.
Summary
SB 446 would substantially revise Connecticut law governing pharmacy benefits managers (PBMs) under title 38a. The bill prohibits PBMs from imposing post-transaction fees or reimbursement clawbacks on pharmacies, requires manufacturer rebates and similar financial incentives to be passed through to covered persons at the point of sale, and decouples PBM compensation from drug prices. It also bars fees for formulary placement or tier access and prohibits PBMs from steering patients toward more expensive drugs when less expensive, clinically appropriate alternatives are available.
The bill further adds transparency and oversight requirements for PBM-related contracting. It would require any group purchasing organization contracting with a PBM in the state to be U.S.-incorporated and to disclose fees and administrative costs, and it directs the Attorney General to oversee PBM operations to enforce rebate transparency and clawback prohibitions. The bill’s stated purpose is to reform PBM practices and establish a duty of care owed by PBMs.
Impact
If enacted, the bill would create new statutory restrictions on PBM business practices in Connecticut and expand state oversight of prescription drug middlemen. It would affect PBMs, pharmacies, drug manufacturers, group purchasing organizations, and insured consumers by changing how rebates, fees, reimbursements, and formulary decisions are handled. The measure would likely alter contract structures and compliance obligations in the pharmacy supply chain and could reduce certain PBM revenue streams while increasing transparency for patients and regulators.
Sentiment
Because there are no committee transcripts or recorded votes provided, there is no direct evidence of legislative debate or formal support/opposition in the available record. Based on the bill text, the measure appears strongly reform-oriented and consumer-protective, with an emphasis on lowering drug costs, increasing transparency, and limiting PBM practices viewed as harmful to pharmacies and patients.
Contention
The likely points of contention are the bill’s restrictions on PBM compensation and contracting practices, especially the bans on clawbacks, post-transaction fees, and formulary-related charges. PBMs and related industry groups may object that these limits interfere with existing business models, rebate negotiations, and plan design, while pharmacies, consumer advocates, and supporters of drug pricing reform are likely to favor the bill’s transparency and pass-through requirements. The Attorney General oversight provision and the proposed duty of care could also be contested as expanding liability and regulatory authority.